Search Results
Sep 07, 2026, 00:29 ET Hisense přináší na veletrh IFA 2026 realistické barvy, pohodlí pro oči a pohlcující zábavu
multimedia:https://www.prnewswire.com/news-releases/hisense-pinai-na-veletrh-ifa-2026-realisticke-barvy-pohodli-pro-oi-a-pohlcujici-zabavu-302871031.html
More news about: Hisense
Sep 04, 2026, 22:12 ET Hisense prináša na veľtrh IFA 2026 realistické farby, pohodlie pre oči a pohlcujúcu zábavu
multimedia:https://www.prnewswire.com/news-releases/hisense-prinaa-na-vetrh-ifa-2026-realisticke-farby-pohodlie-pre-oi-a-pohlcujucu-zabavu-302870570.html
More news about: Hisense
Aug 24, 2026, 08:42 ET James T. Brunz, MD Recognized by Abbott Neuromodulation as a Spinal Cord Stimulation Center of Excellence Physician
Orthopedic InstituteFounded in 1972, Orthopedic Institute (OI) is an independent physician group specializing in orthopedics, sports medicine, and interventional spine and pain care. With 21 physicians and more than 225 employees, OI serves patients across South Dakota, Minnesota, and Iowa from its
More news about: Orthopedic Institute
Aug 14, 2026, 09:08 ET Deeper Insights, Better Analytics: Bybit Options Close the Data Gap Between Retail and Institutional Traders
as expiry approaches.Position Structure: A breakdown of open interest and volume by notional value or contract count, the call-to-put OI ratio, and 24-hour taker buy/sell activity.Market Activity: Live tracking of Gamma Exposure (GEX), flip point levels, and large or mega
More news about: Bybit
Aug 14, 2026, 08:57 ET Deeper Insights, Better Analytics: Bybit Options Close the Data Gap Between Retail and Institutional Traders
as expiry approaches.Position Structure: A breakdown of open interest and volume by notional value or contract count, the call-to-put OI ratio, and 24-hour taker buy/sell activity.Market Activity: Live tracking of Gamma Exposure (GEX), flip point levels, and large or mega
More news about: Bybit
Aug 11, 2026, 08:00 ET Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant
More news about: Sentynl Therapeutics
Aug 06, 2026, 10:20 ET Los futuros y opciones de divisas latinoamericanas de CME Group alcanzan nuevos récords en el primer semestre de 2026
aumento de 38% anual), mientras que el interés abierto (OI) superó los 6,200 millones de dólares.Los futuros sobre el real brasileño registraron un ADV récord de 740 millones de dólares (un incremento de 18% anual), con un interés abierto (OI) superior a 2,600 millones de dólares. Por su parte,
More news about: CME Group
Aug 06, 2026, 10:13 ET CME Group registra recorde de negociações de futuros e opções de moedas latino-americanas no primeiro semestre de 2026
contratos futuros e opções de peso mexicano (MXN) e real brasileiro (BRL) de volume médio diário (ADV, na sigla em inglês) e de interesse em aberto (OI, na sigla em inglês) durante o primeiro semestre de 2026. O anúncio conta ainda com o apoio do Itaú Unibanco, que destaca a plataforma do CME como uma
More news about: CME Group
Aug 06, 2026, 09:16 ET CME Group Latin American FX Futures and Options Hit New Records in H1 2026
ADV.Mexican peso futures reached $2.2 billion ADV (up 38% year-on-year), as open interest (OI) expanded to over $6.2 billion.Brazilian real futures reached a record $740 million ADV (up 18% year-on-year) as OI surpassed $2.6 billion, while Brazilian real options delivered a record-setting first
More news about: CME Group
Aug 05, 2026, 03:31 ET OI Investors Have Opportunity to Join O-I Glass, Inc. Fraud Investigation with SBS Law
OI) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading
More news about: Schall, Brown & Schwartz LLP
Jul 31, 2026, 10:07 ET OI SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving O-I Glass
eligible to participate in the OI investigation? A: Investors who purchased OI stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares. Q: What do OI investors need to do right
More news about: SueWallSt.com
Jul 30, 2026, 15:48 ET O-I Glass Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into O-I Glass (OI)
eligible to participate in the OI investigation? A: Investors who purchased OI stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.Q: What do OI investors need to do right
More news about: Levi & Korsinsky, LLP
Jul 30, 2026, 06:50 ET Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
Operating Income ("OI")$ 451.6
More news about: Labcorp Holdings Inc
Jul 22, 2026, 16:01 ET TI reports second quarter 2026 financial results and shareholder returns
1,563Other income (expense), net (OI&E)
More news about: Texas Instruments Incorporated
Jul 01, 2026, 06:39 ET Zinc Media Group: STARS OF SCIENCE EXTENDS CASTING DEADLINE TO JULY 10 AS GLOBAL RESPONSE DRIVES RECORD INTEREST FOR SEASON 18
https://www.dropbox.com/scl/fo/j6zjam5r1dsdht44xb03v/ADVbIe_6e0ntzmZfdceeVB0?rlkey=2ai3276d4abl6snpvr1n9bynj&st=oi24ee41&dl=0 For More Information, check out
More news about: Zinc Media Group
Jul 01, 2026, 06:36 ET Zinc Media Group: STARS OF SCIENCE EXTENDS CASTING DEADLINE TO JULY 10 AS GLOBAL RESPONSE DRIVES RECORD INTEREST FOR SEASON 18
https://www.dropbox.com/scl/fo/j6zjam5r1dsdht44xb03v/ADVbIe_6e0ntzmZfdceeVB0?rlkey=2ai3276d4abl6snpvr1n9bynj&st=oi24ee41&dl=0 For More Information, check out
More news about: Zinc Media Group
Jun 30, 2026, 08:30 ET CME Group to Launch Single Stock Futures on July 27
and open interest (OI) highs in 2026 including:Futures and options average daily volume (ADV) of 8.6 million contracts and average OI of 11.7 million contracts.Futures ADV of 7.2 million contracts, up 12% year-over-year, and record average futures OI of 5.4 million contracts.The
More news about: CME Group
Jun 30, 2026, 06:00 ET MEXC SpaceX Products See Surging Demand as Cumulative Futures Trading Volume Surpasses $7.1 Billion
its IPO on June 12, the SPCXUSDT perpetual futures has accumulated over $7.1 billion in trading volume, with open interest (OI) peaking at $25 million — an increase of more than 26 times from its launch.
More news about: MEXC
Jun 30, 2026, 06:00 ET MEXC SpaceX Products See Surging Demand as Cumulative Futures Trading Volume Surpasses $7.1 Billion
its IPO on June 12, the SPCXUSDT perpetual futures has accumulated over $7.1 billion in trading volume, with open interest (OI) peaking at $25 million — an increase of more than 26 times from its launch.
More news about: MEXC
Jun 11, 2026, 00:54 ET Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
application potential in obesity and metabolic health.First Disclosure of OI25 Data: Post–Discontinuation Weight Regain Reduced 2.7–FoldThe focal point of this ADA presentation was the first–time disclosure of the OI25 animal study data. The study evaluated the post–discontinuation weight maintenance
More news about: Caliway Biopharmaceuticals
Jun 10, 2026, 01:08 ET 康霈於美國糖尿病協會 ADA 2026 首度公開 CBL-514 併用「瘦瘦針」最新動物數據OI25, 展現「減緩復胖、改善代謝」雙重潛力
年會的發表講者。大會現場反響熱烈，吸引了許多跨領域專家與各國藥廠代表駐足提問，甚至有臨床試驗主持人特地前來追問最新實驗進程，並指出許多患者已經迫不及待希望能參與後續的臨床試驗。」康霈指出，先前完成的 OI21 與 OI23 動物實驗已充分證實，不論是與諾和諾德（Novo Nordisk）的 Semaglutide 或是禮來（Eli Lilly）的 Tirzepatide 這兩大市售主流「瘦瘦針」併用，CBL-514 皆展現出減重增效、停藥防復胖、顯著減少皮下及內臟脂肪，以及改善全身性代謝指標等多重潛力。本次 ADA 年會首度揭露的 OI25 數據，則讓這項領先趨勢得到了更強而有力的科學驗證。展望未來，康霈將持續深化 CBL-514 與 GLP-1R 類藥物併用之研究，並規劃於今年下半年正式推進人體臨床試驗，持續加速
More news about: 康霈生技
Jun 04, 2026, 06:00 ET MEXC Tops New Contract Listings in CoinGecko's 2026 State of Crypto Perpetuals Report
exchanges as of April 2026.Ranking No. 4 Globally in Open Interest Market ShareAs of April 2026, MEXC held an 11.4% open interest (OI) market share among the top 11 centralized perpetual exchanges, ranking No. 4 globally. This reflects a significant number of users holding open positions
More news about: MEXC
Jun 04, 2026, 06:00 ET MEXC Tops New Contract Listings in CoinGecko's 2026 State of Crypto Perpetuals Report
exchanges as of April 2026.Ranking No. 4 Globally in Open Interest Market ShareAs of April 2026, MEXC held an 11.4% open interest (OI) market share among the top 11 centralized perpetual exchanges, ranking No. 4 globally. This reflects a significant number of users holding open positions
More news about: MEXC
May 28, 2026, 07:59 ET Bybit Announces Transition to Single-Counted Open Interest Reporting to Enhance Market Transparency
exchange by trading volume, announced an update to its Open Interest (OI) calculation methodology, effective June 11, 2026. The exchange will transition from bilateral (dual-sided) OI counting to unilateral (single-counted) OI measurement. The move aligns Bybit's reporting framework with methodologies
More news about: Bybit
May 28, 2026, 07:29 ET Bybit Announces Transition to Single-Counted Open Interest Reporting to Enhance Market Transparency
exchange by trading volume, announced an update to its Open Interest (OI) calculation methodology, effective June 11, 2026. The exchange will transition from bilateral (dual-sided) OI counting to unilateral (single-counted) OI measurement. The move aligns Bybit's reporting framework with methodologies
More news about: Bybit